Etiology of Multiple Myeloma: A Case-Control Study
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
FM 140 vs FM100 Study in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
- Status
- COMPLETED
- Phase
- PHASE2
QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression
- Status
- COMPLETED
- Phase
- PHASE3
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
GEM05 for Patients With Multiple Myeloma Under 65 Years
- Status
- COMPLETED
- Phase
- PHASE3
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1